drug
as of 2026-07-01Pyridoxine
pyridoxine
MeSH D011736
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Beersheva Mental Health Center
4 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
SchizophreniaSchizophrenia Spectrum and Other Psychotic DisordersDyskinesiasOxidative StressDrug Induced Movement Disorder, UnspecifiedSchizophreniaAcute SchizophreniaTardive DyskinesiaNeurologic ManifestationsPsychotic DisordersMovement DisordersAntipsychotic AgentsTardive DyskinesiaSigns and Symptoms
Trials
4
Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia
NCT03287778—Completed
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
NCT03790345Phase 2, Phase 3Unknown
Pyridoxal Kinase Activity in Tardive Dyskinesia
NCT01908452Phase 3Withdrawn
Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00140166Phase 4Completed
KOLs & investigators
4
Prof. Vladimir Lerner, MD, PhDKOL score 5
RH Belmaker, MDKOL score 0
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
trial
indication
indication
indication
indication
KOL
Prof. Vladimir Lerner, MD, PhD
personKOL score 5
RH Belmaker, MD
personKOL score 0
Lars F. Jarskog, MD
personKOL score —
Lia LO Sanders, MD, PhD
personKOL score —